Paris PSVD Meeting: International Consensus and Clinical Research Highlights for Porto-Sinusoidal Vascular Disease

In December 2025, an international PSVD meeting in Paris brought together more than 140 in-person attendees and around 300 online participants.
The meeting was supported by VALDIG, COST EURO-VALDI-NET, ERN RARE-LIVER and FILFOIE.

ern_psvd_workshop_paris_2026.jpg
Back to overview

On 4–5 December 2025, the Paris PSVD Meeting brought together more than 140 in-person attendees at the Conservatoire National des Arts et Métiers (CNAM) in Paris, alongside approximately 300 online participants across the two days. Organised by Laure Elkrief, Virginia Hernandez-Gea, and Pierre-Emmanuel Rautou, with the support of VALDIG (Vascular Liver Disease Group), COST EURO-VALDI-NET, ERN RARE-LIVER and FILFOIE, this international event focused on shaping current knowledge and defining future directions for Porto-Sinusoidal Vascular Disease (PSVD).

Porto-Sinusoidal Vascular Disease remains a complex and challenging rare liver condition. The meeting provided an opportunity to address current knowledge gaps, review diagnostic standards, discuss management strategies, and establish consensus frameworks for upcoming clinical trials.

Key Highlights and Scientific Sessions

Day 1: Current Knowledge and Future Directions for PSVD

The first day brought together global specialists from across Europe, North America, and beyond. Discussions covered the pathophysiology and conditions associated with PSVD, breakthroughs in genetic and preclinical models, and refinements in diagnostic imaging and pathology. Several important clinical challenges were discussed, such as distinguishing PSVD progression from cirrhosis, managing nodules, and adapting treatments for paediatric transition to adulthood.

Day 2: Consensus Statement on Clinical Trials in PSVD

The second day provided a collaborative platform to set standard guidelines for future clinical research. Through dedicated breakout sessions, working groups worked on refining inclusion criteria, evaluating surrogate markers of outcome, and identifying robust hard endpoints for trials. Sessions also featured discussions on innovative trial designs for rare diseases and the integration of health-related quality of life.

Outcome and Watch the Sessions